A 38-year-old man with a 2-year history of Meniere disease (left ear) presents with acute severe vertigo, nausea, and vomiting. He has already tried dietary sodium restriction and diuretics without sustained benefit. He reports that episodes are now occurring twice weekly, significantly affecting his work. His audiometry shows progressive sensorineural hearing loss across all frequencies. Which of the following is the most appropriate next step in management?

Explanation

## Management of Refractory Meniere Disease ### Clinical Context This patient has **refractory Meniere disease** (frequent episodes despite medical therapy) with progressive hearing loss. He requires escalation from medical to interventional management. ### Treatment Algorithm ```mermaid flowchart TD A[Meniere Disease Diagnosis]:::outcome --> B{Symptom severity<br/>& frequency?}:::decision B -->|Mild-moderate,<br/>infrequent| C[First-line medical:<br/>Low-sodium diet,<br/>diuretics, betahistine]:::action B -->|Frequent/severe<br/>despite medical Rx| D{Hearing preservation<br/>priority?}:::decision D -->|Yes| E[Endolymphatic sac<br/>decompression]:::action D -->|No/already<br/>advanced loss| F[Intratympanic gentamicin]:::action C --> G{Response?}:::decision G -->|Good| H[Continue medical Rx]:::outcome G -->|Poor| D E --> I[Vertigo control<br/>with hearing preservation]:::outcome F --> J[Vertigo control<br/>Hearing loss accepted]:::outcome ``` **Key Point:** The choice between intratympanic gentamicin and endolymphatic sac decompression depends on the priority: if hearing preservation is critical, choose surgery; if hearing is already significantly impaired or the patient prioritizes vertigo control, choose gentamicin. ### Interventional Options Comparison | Feature | Endolymphatic Sac Decompression | Intratympanic Gentamicin | Vestibular Nerve Section | |---------|----------------------------------|--------------------------|-------------------------| | **Vertigo control** | 60–70% | 80–90% | >95% | | **Hearing preservation** | Good (often improves) | Poor (ototoxic) | Excellent | | **Invasiveness** | Mastoid surgery | Office procedure | Translabyrinthine surgery | | **Tinnitus improvement** | Variable | Variable | Variable | | **Best for** | Early-moderate disease, hearing priority | Refractory disease, hearing loss acceptable | Severe bilateral disease, hearing already lost | **High-Yield:** Intratympanic gentamicin is a **vestibulotoxic aminoglycoside** that selectively ablates vestibular hair cells while sparing cochlear function at low doses. It is highly effective for vertigo control in refractory Meniere disease. ### Why Intratympanic Gentamicin Is Appropriate Here 1. **Refractory disease:** Patient has failed first-line medical therapy (diuretics, dietary restriction) 2. **Frequent episodes:** Twice weekly vertigo is significantly impacting quality of life 3. **Progressive hearing loss:** Audiometry shows worsening across all frequencies, indicating advanced cochlear involvement 4. **Hearing already compromised:** Since hearing is already deteriorating, the ototoxic risk of gentamicin is acceptable **Clinical Pearl:** Gentamicin is administered via intratympanic injection (0.26 mL of 26.7 mg/mL solution) as a single dose or repeated doses. Vertigo control occurs in 80–90% of patients. The procedure can be repeated if needed. ### Dosing & Administration - **Single-dose protocol:** 0.26 mL intratympanic injection, may repeat after 4 weeks - **Low-dose protocol:** Weekly injections for 4 weeks (lower ototoxicity) - **Monitoring:** Audiometry before and after treatment; caloric testing to assess vestibular response **Warning:** Gentamicin is irreversibly ototoxic. It should NOT be used in patients with serviceable hearing in the contralateral ear or in early-stage disease where hearing preservation is possible. ### Why Other Options Are Suboptimal **Increasing diuretics + betahistine:** This patient has already failed first-line medical therapy. Escalating doses without changing the treatment modality is unlikely to provide additional benefit and delays definitive intervention. **Endolymphatic sac decompression:** While this is a hearing-preserving option, the patient's hearing is already significantly impaired (progressive loss across all frequencies). The priority shifts from hearing preservation to vertigo control. Decompression has lower vertigo control rates (60–70%) compared to gentamicin (80–90%). **Repeat MRI:** MRI was presumably normal at diagnosis (to exclude retrocochlear pathology). Repeating it without new red flags (asymmetric sensorineural loss, facial weakness, etc.) is not indicated and delays treatment.